Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:51 (1 July), doi:10.1136/bmj.333.7557.51
| The first 150 words of the full text of this article appear below. |
The call by two US renal specialists for active consideration of "the controlled initiation and study of potential regimens that may increase donor kidney supply in the future in a scientifically and ethically responsible manner" through cash payments is an uncomfortable challenge (Kidney International 2006;69: 960-2[CrossRef][Web of Science][Medline]). However, it is not one that necessarily requires us to venture far into new territory. We already have well regulated tariffs for the valuing of various body parts, including kidneys. And the valuation that the two specialists suggest$40 000 (£22 000;
32 000), which prize winning economistis compatible with these tariffs.
| We already permit the sale of body parts and fluids on the market model
|
Several "incentive models" (American Journal of Transplantation 2005;5: 15-20) already operate for the involvement of people in medical activities that do not benefit themselves directly.
Sue Rabbitt Roff, senior research fellow
Centre for Medical Education, Dundee University Medical School s.l.roff@dundee.ac.uk
Read all Rapid Responses